Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis

Table 1

Tumor properties of the 25 patients with GEP-NETs.

Case no.	Age	Sex	NET type	Tumor grade	KI-67 index (%)	Type of therapy	Times of therapy
1	72	M	g-NET	3	80	Etoposide and cis-platinum	6
2	71	M	g-NET	3	80	Etoposide and cis-platinum	2
3	49	F	p-NET	2	20	Etoposide and cis-platinum	2
4	47	M	SI-NET	3	90	Etoposide and cis-platinum	4
5	28	F	r-NET	3	80	Etoposide and cis-platinum	2
6	45	M	SI-NET	3	70	Etoposide and cis-platinum	3
7	66	M	p-NET	3	80	Etoposide and cis-platinum	2
8	59	M	r-NET	2	15	Everolimus	3
9	49	F	r-NET	1	1	Everolimus	2
10	55	F	p-NET	2	10	Everolimus	4
11	39	M	SI-NET	1	<1	Octreotide acetate	6
12	66	M	p-NET	2	5	Octreotide acetate	2
13	59	M	r-NET	2	15	Octreotide acetate	3
14	40	M	p-NET	2	8	Octreotide acetate	4
15	42	F	SI-NET	2	7	Octreotide acetate	6
16	69	M	p-NET	2	1	Octreotide acetate	4
17	62	F	SI-NET	1	<1	Octreotide acetate	3
18	37	M	SI-NET	2	5	Octreotide acetate	3
19	71	M	g-NET	3	80	Xeloda and temozolomide	4
20	42	F	p-NET	3	50	Sunitinib	3
21	56	M	r-NET	2	5	Sunitinib	2
22	46	F	p-NET	2	10	Sunitinib	5
23	29	M	p-NET	2	15	Sunitinib	4
24	37	M	SI-NET	2	5	Sunitinib	5
25	36	F	p-NET	1	<1	Sunitinib	8

g-NET, gastric neuroendocrine tumors; p-NET, pancreatic neuroendocrine tumors; SI-NET, small intestinal pancreatic neuroendocrine tumors; r-NET, rectal pancreatic neuroendocrine tumors.